New FDA approved drugs in 2024

Drug: Tovorafenib (oral)
Indication: To treat relapsed or refractory pediatric low-grade glioma
Mechanism: Kinase inhibitor

Drug: Danicopan (oral)
Indication: To treat extravascular hemolysis with paroxysmal nocturnal hemoglobinuria
Mechanism: proximal, complement alternative pathway factor D inhibitor.
Drug: Vadadustat (oral)
Indication: To treat anemia due to chronic kidney disease
Mechanism: hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor

Drug: Givinostat (oral)
Indication: Duchenne muscular dystrophy in individuals aged 6 years and older
Mechanism: histone deacetylase inhibitor

Drug: Aprocitentan (oral)
Indication: To treat hypertension
Mechanism: Endothelin receptor antagonist

свернуть